NASA is looking for volunteers. Anyone who can help is welcome, so if you ever dreamed of being an astronaut but never got the chance, now you can become part

Numerous market analyses have shown that over the next five years, demand for lithium-ion batteries for everything from personal electric devices to grid-scale energy storage is expected to grow dramatically.
To meet this demand, battery manufacturing needs to be faster, cheaper, more dependable, less energy-intensive and less wasteful. A key part of lithium-ion battery manufacturing with significant room for improvement is the processing and fabrication of electrodes.
To facilitate advances in this area, researchers at the U.S. Department of Energy’s (DOE) Argonne National Laboratory have conducted a comprehensive review of the scientific literature on advanced electrode processing technologies. The findings are published in the journal Nature Reviews Clean Technology.
In 2009, NASA’s Chandra X-ray Observatory released a captivating image: a pulsar and its surrounding nebula that is shaped like a hand. Since then, astronomers have used Chandra and other telescopes to continue to observe this object. Now, new radio data from the Australia Telescope Compact Array (ATCA) has been combined with Chandra’s X-ray data to provide a fresh view of this exploded star and its environment, to help understand its peculiar properties and shape.
At the center of this new image lies the pulsar B1509-58, a rapidly spinning neutron star that is only about 12 miles in diameter. This tiny object is responsible for producing an intricate nebula (called MSH 15–52) that spans over 150 light-years, or about 900 trillion miles. The nebula, which is produced by energetic particles, resembles a human hand with a palm and extended fingers pointing to the upper right in X-rays.
The collapse of a massive star created the pulsar when much of the star crashed inward once it burned through its sustainable nuclear fuel. An ensuing explosion sent the star’s outer layers outward into space as a supernova.
Multiple sclerosis (MS) is an autoimmune disease where the body’s immune system mistakenly attacks the central nervous system, leading to the destruction of myelin, the protective sheath surrounding nerve fibres. This damage is a leading cause of neurological disability in young adults.
In the early stages of MS, certain cells possess the capacity to partially repair this damage by generating new myelin. However, this regenerative ability reduces significantly in the later, chronic progressive stage of the disease. This decline in repair contributes to further damage to neurons and increasing disability in individuals with progressive MS.
Despite advancements in treatments, current therapies mostly focus on managing symptoms but do not halt or reverse the damage and neurodegeneration caused. This shows the critical need for a more profound understanding of how MS progresses and to explore how stem cell technologies could help MS treatment.
The study, published in the journal Brain, was spearheaded by University of Cambridge scientist Dr. Luca Peruzzotti-Jametti and offers crucial insights into the potential of neural stem cell transplantation in people with progressive MS. While neural stem cell transplants present a promising avenue for repairing the damaged central nervous system, the limits of their capacity to repair are being investigated by researchers.
(Utilizng stem cells for many innovative treatments is not a question of how, but rather when)
A study led by Cambridge researchers has shed light on how neural stem cell grafts could help restore myelin in the central nervous system. The findings suggest that neural stem cell-based therapies hold promise as a potential treatment for chronic demyelinating disorders, particularly progressive multiple sclerosis.
A research team, led by the Universities of Bristol and Cambridge, demonstrated that the polymer material used to make the artificial heart valve is safe following a six-month test in sheep.
Currently, the 1.5 million patients who need heart valve replacements each year face trade-offs. Mechanical heart valves are durable but require lifelong blood thinners due to a high risk of blood clots, whereas biological valves, made from animal tissue, typically last between eight to 10 years before needing replacement.
The artificial heart valve developed by the researchers is made from SEBS (styrene-block-ethylene/butyleneblock-styrene) – a type of plastic that has excellent durability but does not require blood thinners – and potentially offers the best of both worlds. However, further testing is required before it can be tested in humans.
An artificial heart valve made from a new type of plastic could be a step closer to use in humans, following a successful long-term safety test in animals.
Scientists are making encouraging progress in developing vaccines to treat cancer, but so far the therapies have been restricted to specific types of tumor. Now new research points the way to a universal vaccine that could attack a wider range of cancers.
The research led by a team at the University of Florida focuses on “waking up” the immune system to better respond to more types of cancerous cell – tumors that would otherwise be missed for a variety of reasons.
“What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anti-cancer reaction,” says neuroscientist Duane Mitchell.